Tarsus Pharmaceuticals (TARS) shares fell about 5% on Wednesday after short seller Culper Research revealed its short position in the stock and published a detailed report accusing the company of using questionable practices to drive sales of its sole product, XDEMVY.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.